Primary_Site,Protocol,Principal_Investigator,Date_Opened,Date_Closed,Study_Phase,Title
Brain and Nervous System,N-1262421,"Abad, A",01/07/2022,,II,(A071702) A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Brain and Nervous System,I-546319,"Abad, A",07/08/2021,03/23/2022,N/A,Expanded Access to SurVaxM for Treatment of Patients with Glioblastoma Who Have No Access to Other Comparable or Alternative Therapy or Have Completed Treatment on a non-Randomized Clinical Trial of SurVaxM and May Benefit from Further Treatment
Brain and Nervous System,P-1281721,"Abad, A",03/08/2022,,II,"A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy"
Brain and Nervous System,I-813720,"Abad, A",12/29/2021,,II,Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Colon,N-626620,"Alarcon Velasco, S",07/15/2020,02/27/2023,II,(S1922) A Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Bladder,I-1523721,"Aly, A",07/16/2021,,N/A,Transurethral Resection of Bladder Tumor (TURBT): Quality Assurance Database
Prostate,I-2018021,"Aly, A",10/07/2021,,N/A,Assessment of Sexual Function and Quality of Sex Life in Patients with Prostate Cancer and their Partners
Breast,I-120807,"Ambrosone, C",12/26/2007,10/18/2022,N/A,The Women's Circle of Health Study
Breast,I-724220,"Ambrosone, C",08/05/2020,,N/A,The New York Breast Cancer Study (NYBCS)
Pancreas,N-750320,"Bain, A",02/05/2021,11/15/2022,N/A,EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
Other Hematopoietic,N-71918,"Bambach, B",10/11/2018,04/15/2022,III,"(ACCL1633) The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)"
"Multiple Sites; Leukemia, other",PH-271115,"Bambach, B",08/03/2016,06/10/2021,III,"(ACCL1333/CV185-155) A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Venous Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (T or B cell) Treated with Asparaginase"
Brain and Nervous System,N-1385821,"Barth, M",07/19/2021,,III,"(ACNS1931) A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations"
Brain and Nervous System,N-564119,"Barth, M",01/06/2020,,III,(ACNS1831) A Phase 3 Randomized Study of Selumetinib (IND # 77782) Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Brain and Nervous System,N-632820,"Barth, M",02/26/2020,,III,"(ACNS1833) A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)"
"Leukemia, other",I-62318,"Barth, M",02/08/2019,05/05/2022,N/A,"Matched Targeted Therapy (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome"
Other Hematopoietic,P-522219,"Barth, M",06/23/2020,,II,Acute GVHD Suppression using Costimulation Blockade to Expand Non-malignant Transplant (ASCENT)
Unknown Sites,I-1507721,"Besharat Shafiei, S",07/15/2021,,N/A,Analysis of physical ergonomic risk factors in human-surgical robot shared environment
Multiple Sites,I-1720121,"Besharat Shafiei, S",10/27/2021,,N/A,"Real-Time Evaluation of Severity of Perceived Pain in Patients with Cancer by Using Functional Near-Infrared Spectroscopy (fNIRS), and Investigation of Pain Relief Utilizing Virtual Reality Technologies"
Breast,I-60217,"Bonaccio, E",10/18/2018,,N/A,Photoacoustic Imaging of Human Breast
Multiple Sites,I-1946021,"Bouchard, E",10/29/2021,,N/A,Mindfulness Meditation
Unknown Sites,I-2048021,"Bouchard, E",01/07/2022,,N/A,A Virtual Intervention to Improve Medication Adherence in Pediatric Cancer: MedSupport
Unknown Sites,I-288716,"Bouchard, E",06/08/2017,01/13/2023,N/A,"The Influence of Social Network Size, Composition and Function on Psychological Outcomes of Pediatric Cancer Caregiving: Relationships across Time and around Periods of Distress"
"Leukemia, other",I-1832021,"Bouchard, E",09/01/2021,,N/A,Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Studies 1 and 2
Unknown Sites,I-589019,"Bouchard, E",05/14/2020,01/05/2023,N/A,Examining Exposure and Adaptation to Stressors Within Patient-Caregiver Dyads and Relationships with Markers of Immune Suppression (Internal Title: Care Well)
Bones and Joints,IC-1840021,"Buxbaum, N",12/17/2021,,II,BMT CTN 1904 Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
Other Hematopoietic,P-2086021,"Buxbaum, N",08/15/2022,,II/III,"Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to assess the safety and efficacy of ALVR105 (Viralym-M) Compared to Placebo for the prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or disease, in High-risk Patients after Allogeneic Hematopoietic Cell Transplant"
Lymphoid Leukemia,I-466719,"Buxbaum, N",04/21/2020,,II,A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative
Other Hematopoietic,IC-1113721,"Buxbaum, N",06/15/2022,,N/A,PROJECT SICKLE CURE
Unknown Sites,IC-1479721,"Buxbaum, N",02/16/2022,,N/A,Applied Biomarkers to Minimize Long Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Pediatric Transplantation & Cellular Therapy Consortium (PTCTC)
Multiple Sites; Bladder,I-69518,"Chatta, G",04/10/2019,12/01/2022,II,(CITN-14) Randomized Phase II study of Atezolizumab (MPDL3280A) plus Recombinant Human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma
Prostate,I-63418,"Chatta, G",06/07/2019,07/20/2022,I/II,Phase Ib/II Study of Enzalutamide with Venetoclax (ABT-199) in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Prostate,I-1373721,"Chatta, G",01/26/2022,,I,A Phase 1b Clinical Trial: Improving Outcomes with Androgen Pathway Inhibitors by Targeting DNA Methyltransferase Activity
Prostate,I-287816,"Chatta, G",04/03/2017,,I/II,"Phase IB/II Study of Enzalutamide with Ribociclib in Patients with Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer that retains RB Expression"
Prostate,I-72118,"Chatta, G",01/03/2019,,N/A,Nutrition and Exercise Interventions to Reduce Androgen Deprivation Therapy-induced Obese Frailty in Survivors of Advanced Prostate Cancer
Prostate,I-77318,"Chatta, G",11/29/2019,,II,Randomized Phase 2 Study: Neoadjuvant conditioning of prostate cancer tumor microenvironment using a novel chemokine-modulating regimen
Prostate,P-1658021,"Chatta, G",07/07/2022,,I,"A Phase 1 Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients with Metastatic Castration-Resistant Prostate Cancer"
Prostate,P-1900021,"Chatta, G",06/24/2022,03/15/2023,I/II,"A PHASE 1/2 FEASIBILITY, SAFETY, AND ACTIVITY STUDY OF PSCA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR ENGINEERED T CELLS (BPX-601) IN SUBJECTS WITH PREVIOUSLY TREATED ADVANCED SOLID TUMORS"
Prostate,IC-1796321,"Chatta, G",06/30/2022,,I,A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer
Prostate,P-637520,"Chatta, G",09/30/2021,,I/II,A Phase 1/2 Study of REGN5678 (anti-PSMAxCD28) with Cemiplimab (anti-PD-1) in Patients with Metastatic Castration-resistant Prostate Cancer (R5678-ONC-1879)
Other Hematopoietic,I-53817,"Chen, G",05/01/2018,08/23/2022,N/A,The effect of extra-physiologic oxygen shock / stress (EPHOSS) on human hematopoietic stem cell viability and multi-potency
Other Hematopoietic,I-734920,"Chen, G",06/15/2021,08/04/2022,II,Acalabrutinib for chronic graft versus host disease
Other Hematopoietic,P-650420,"Chen, G",04/09/2021,12/23/2022,III,"Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant"
Other Hematopoietic,P-764520,"Chen, G",02/15/2022,,I/II,"Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients with Respiratory Viral Infections After Hematopoietic Cell or Solid Organ Transplant (P-106-001)"
,P-81618,"Chen, G",12/20/2019,02/03/2022,I/II,"(EQ001-aGVHD-001) A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects with Newly Diagnosed Acute Graft Versus Host Disease"
Other Hematopoietic,I-735120,"Chen, G",02/17/2021,12/02/2022,N/A,RG1006823: Predicting the Quality of Response to Specific Treatments (PQRST): Chronic GVHD Cohort
Other Hematopoietic,I-590019,"Chen, G",08/27/2020,,N/A,Close Assessment and Testing for Chronic GVHD (The CATCH Study)
Lung,NCG-263614,"Chen, H",04/21/2016,08/17/2022,III,(E4512 )A randomized  Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Lung,NCG-263814,"Chen, H",01/13/2015,,III,(A151216) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Lung,N-1039720,"Chen, H",02/25/2021,05/20/2022,III,EA5182: Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer NSCLC)
"Melanoma, Skin",I-278415,"Chowdhry, V",02/07/2017,,I/II,(12-100) Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) or Photon (IMRT) with Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas
Non-Hodgkin's Lymphoma,N-1598021,"Cortese, M",08/19/2021,,II/III,"(S1918) A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements."
Unknown Sites,I-80418,"Dean, G",07/02/2019,,N/A,Efficacy of Nurse-Delivered Brief Behavioral Treatment to Self-Manage Insomnia in Cancer Survivors
,I-70818,"Demmy, T",07/16/2020,,I/II,"Phase I/ II Study of Pulmonary Suffusion to Control Minimal Residual Disease in
Resectable or Ablatable Sarcoma or Colorectal Pulmonary Metastases"
Lung,I-649220,"Demmy, T",06/18/2021,,N/A,Registry Trial of Active Surveillance for Multifocal Ground Glass Opacities (GGOs)
Lung,P-825720,"Dexter, E",10/19/2021,,II,CHIO3 Trial: CHemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
"Lung; Lip, Oral Cavity and Pharynx",I-286816,"Dy, G",12/22/2016,,I/II,A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination with the Anti-PD1 Therapy in Patients with Advanced NSCLC or Squamous Head and Neck Cancer
Lung,I-281616,"Dy, G",06/29/2017,02/08/2022,I/II,"A Phase I/II Open-label Study of Nimotuzumab in Combination with Nivolumab
in Patients with Advanced Non-small Cell Lung Cancer or Squamous Head and Neck
Cancer"
Lung,I-691720,"Dy, G",07/02/2021,,II,A Phase II Trial of Lamivudine in Combination with Chemoimmunotherapy in Patients with Extensive Stage SCLC
Lung,I-82319,"Dy, G",02/13/2020,01/24/2023,II,Randomized Phase II Study of Pembrolizumab 200mg Every 12Weeks Versus Every 3 Weeks in NSCLC with Clinical Benefit to Pembrolizumab Monotherapy: Multicenter International Study
Multiple Sites,P-70918,"Dy, G",01/31/2019,09/19/2022,I,"AMG 510 20170543 A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors with KRAS p.G12C  Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation  (CodeBreak 100)."
Lung,P-1195721,"Dy, G",11/24/2021,,II,"A PHASE 2 STUDY OF Mecbotamab Vedotin (CA3011) ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHO HAD PRIOR DISEASE PROGRESSION ON or are Intolerant to a PD-1/L1, EGFR, OR ALK INHIBITOR"
Lung,P-1059120,"Dy, G",05/26/2021,04/29/2022,I/II,"MasterKey-01: A Phase 1/2, Open-Label, Two-Part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients with Advanced Solid Malignancies"
Lung,P-835120,"Dy, G",06/22/2021,,I/II,"A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 with Atezolizumab in Patients with Advanced Cancers Associated with Expression of Delta-like Canonical Notch Ligand 3 (DLL3)"
Lung,P-933720,"Dy, G",01/20/2022,,II,A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer
Multiple Sites,P-73318,"Dy, G",05/30/2019,,I,"A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)"
Lung,P-1794021,"Dy, G",06/24/2022,03/01/2023,II,"A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies"
Lung,P-499719,"Dy, G",07/08/2021,,II,"Open-label, single-arm trial to evaluate antitumor activity, safety, and pharmacokinetics of SAR408701 used in combination with ramucirumab in metastatic, nonsquamous, non small-cell lung cancer (NSQ NSCLC) patients with CEACAM5-positive tumors, previously treated with platinum-based chemotherapy and an immune checkpoint inhibitor"
Lung,P-61618,"Dy, G",10/19/2018,06/25/2022,II,"A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)"
Lung,I-1806221,"Dy, G",01/26/2022,,N/A,Exosomal Expression of Tumor Biomarkers
Lung,I-2136121,"Dy, G",03/25/2022,,N/A,"PROJECT IOTA: Multidisciplinary Workflow Optimization to Overcome 
Challenges in Biomarker Testing and to Expedite Biomarker-based Treatment 
Decisions for Patients with NSCLC"
Lung,I-945720,"Dy, G",01/08/2021,,N/A,Patients  Preferences for Adjuvant Osimertinib or Atezolizumab for NSCLC after Complete Surgical Resection.
Multiple,P-40016,"Fabiano, A",04/07/2017,06/30/2022,N/A,"Vigilant Observation of Gliadel Wafer Implant (VIGILANT) Registry: A multicenter, observational registry to collect information on the safety and effectiveness of Gliadel Wafer (Carmustine Implant) used in usual medical practice"
Brain and Nervous System,I-286416,"Fenstermaker, R",09/15/2016,,N/A,Non-Therapeutic Exploratory Study of Serum Molecular Markers in Brain Tumor Patients Undergoing Surgical Resection of their Tumors
Pancreas,IC-1171721,"Fountzilas, C",06/04/2021,,I/II,(10366) A Phase I/2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the treatment of Locally Advanced Pancreatic Adenocarcinoma
Pancreas,N-1191721,"Fountzilas, C",07/22/2021,,II,(S2001) Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations
Colon; Rectum,I-444019,"Fountzilas, C",11/08/2019,09/20/2022,II,"A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO)"
Multiple,I-650120,"Fountzilas, C",05/28/2021,,I,A Phase I Study of Trifluridine/ Tipiracil plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers
Pancreas; Colon,I-797920,"Fountzilas, C",12/30/2021,,N/A,Perioperative Analysis of Binimetinib and Palbociclib in RAS-driven tumors
Multiple,P-706120,"Fountzilas, C",04/13/2022,,I,"Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation"
Pancreas,P-1688021,"Fountzilas, C",11/22/2021,,I/II,A PHASE 1b/2 RANDOMIZED STUDY OF AVB-S6-500 PLUS NAB-PACLITAXEL AND GEMCITABINE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA
Multiple,P-569719,"Fountzilas, C",07/26/2021,02/21/2023,I,"9801-CL-0101 A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral 
Injection as a Single Agent and in Combination with Pembrolizumab in Subjects with 
Advanced/Metastatic Solid Tumors"
Stomach,P-58917,"Fountzilas, C",01/23/2019,02/23/2022,III,"(ISN 8951-CL-0301) A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362)  Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma"
Multiple Sites,P-75218,"Fountzilas, C",11/05/2019,,II,"(8951-CL-5201): A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma"
Multiple,P-567919,"Fountzilas, C",03/30/2022,03/15/2023,I/II,"A PHASE 1/2, OPEN-LABEL, MULTICENTER, NON-RANDOMIZED, SAFETY AND ACTIVITY STUDY OF HER2-TARGETED DUAL SWITCH CAR-T CELLS (BPX-603) IN SUBJECTS WITH PREVIOUSLY TREATED ADVANCED HER2-POSITIVE SOLID TUMORS"
Pancreas,P-2518022,"Fountzilas, C",08/24/2022,,I,"A Phase 1b/2, Dose-escalation, Randomized, Multi-Center Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma whose Disease has not Progressed on First Line FOLFIRINOX Chemotherapy"
Multiple Sites,P-697120,"Fountzilas, C",03/02/2021,,I/II,"DF6002-001: A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a monotherapy and in combination with Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications"
Stomach; Esophagus,P-71618,"Fountzilas, C",08/11/2020,02/22/2023,II,"(HCRN ESO17-325) A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients with Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) high Metastatic
Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma"
Multiple Sites,P-539719,"Fountzilas, C",09/30/2020,,Early Phase I,"A phase 1, open-label, multiple-ascending dose study to investigate the safety,
pharmacokinetics, pharmacodynamics, and preliminary efficacy of KD033 in subjects with metastatic or locally advanced solid tumors"
Liver,P-1531721,"Fountzilas, C",02/04/2022,,II,"A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 Tablet in Adult Patients with Advanced Cholangiocarcinoma"
Corpus Uteri,N-517719,"Frederick, P",01/23/2020,12/06/2022,III,"NRG-GY018, A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer"
Other Female Genital,P-991720,"Frederick, P",05/23/2022,,I/II,A Phase IB/II Multi-Cohort Study of Targeted Agents with Atezolizumab for Patients with Recurrent or Persistent Endometrial Cancer
Breast,N-1764921,"Fung-Kee-Fung, S",09/16/2021,,III,"NRG-BR007: A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE &#8804; 18 BREAST CANCER"
Breast,N-79418,"Fung-Kee-Fung, S",11/07/2018,,II,(S1706) A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Breast,I-621720,"Fung-Kee-Fung, S",06/02/2020,12/16/2022,N/A,Pilot study of the surveillance and analysis of radiation dermatitis among breast cancer patients using deep machine learning
Breast,I-19-04120,"Gandhi, S",04/07/2022,,II,A Phase IIa Study of Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)
Breast,I-61918,"Gandhi, S",04/24/2019,10/20/2022,II,A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer
Breast,I-68018,"Gandhi, S",02/12/2019,02/15/2022,II,"A Single Arm Phase II Study to evaluate Efficacy of T-DM1 with Palbociclib In The 
Treatment of Patients With Metastatic HER2 Positive Breast Cancer"
"Melanoma, Skin",I-53217,"Gandhi, S",01/31/2018,,I/II,A Phase Ib/II Study of Propranolol with Fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma
Breast,I-73718,"Gandhi, S",12/06/2019,02/21/2023,I,Phase I Clinical Trial Assessing the Combination of Chemokine Modulation with Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Multiple Sites,P-78818,"Gandhi, S",07/03/2019,09/08/2022,I,(ALKS 4230-001) A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001)
Multiple Sites,P-74818,"Gandhi, S",08/01/2019,01/21/2022,I,"A Phase 1 Study with Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Eribulin ORA (HM30181A + Eribulin) in Subjects with Solid Tumors (ATX-ERB-001)"
"Lip, Oral Cavity and Pharynx",P-826120,"Gandhi, S",02/14/2022,,II,"A Phase II Study of cemiplimab, an anti-PD-1 monoclonal antibody, and ISA101b vaccine in patients with recurrent/metastatic HPV16 positive Oropharyngeal Cancer who have experienced disease progression with prior anti-PD-1 therapy"
Breast,IC-1243721,"Gandhi, S",07/29/2021,10/25/2022,N/A,Detection by circulating RNA with OPtimized machine LEarning Technology for Breast Cancer: DROPLET-BC Study
Kidney,N-1095820,"George, S",11/22/2021,,III,(S1931) Phase III Trial of Immunotherapy-Based Drug Combination Therapy With Or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE TRIAL)
Kidney,I-191711,"George, S",10/05/2012,,I/II,A Phase I/ II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients
Kidney,P-1904021,"George, S",12/01/2022,,III,"TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor"
Kidney,P-1471721,"George, S",05/23/2022,12/21/2022,I/II,"A PHASE 1B/2 STUDY OF AVB-S6-500 IN COMBINATION WITH CABOZANTINIB, AVB-S6-500 IN COMBINATION WITH CABOZANTINIB AND NIVOLUMAB, AND AVB-S6-500 MONOTHERAPY IN PATIENTS WITH ADVANCED OR METASTATIC CLEAR CELL RENAL CELL CARCINOMA"
Kidney,P-42016,"George, S",11/29/2017,02/21/2022,III,A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Bladder; Kidney,P-615220,"George, S",04/26/2021,10/31/2022,II,Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab
Kidney,P-844420,"George, S",06/29/2021,12/21/2022,III,"A Phase 3, Open-label, Randomized, Non-Inferiority Trial of Subcutaneous (SC) versus Intravenous (IV) Nivolumab in Advanced, or Metastatic Clear-Cell Renal Cell Carcinoma (RCC) Who Have Received Prior Anti-Angiogenic Therapy"
Bladder,P-834720,"George, S",12/23/2021,10/31/2022,III,A Randomized Open-Label Phase III Study of Sacituzumab Govitecan versus Treatment of Physician's Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer
Kidney,P-845720,"George, S",10/27/2021,,III,"An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as Firstline Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)"
Multiple,P-57417,"George, S",04/17/2018,10/25/2022,I,SGN22E-002 A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Kidney,P-777920,"George, S",09/30/2021,02/20/2023,I,A Phase 1/ 1b Study of SRF388 in Patients with Advanced Solid tumors
Non-Hodgkin's Lymphoma,P-1303721,"Ghione, P",04/12/2022,10/11/2022,II,"An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas ( NAVAL-1 )"
Unknown Sites,I-891720,"Glaser, K",02/19/2021,,N/A,Influence of Yoga on Cancer-Related Stress in Cancer Survivors
,I-629420,"Glaser, K",04/17/2020,02/03/2022,N/A,Assessing Barriers to Care and Task Force Development to Increase Breast Health Equity
,I-2804522,"Glaser, K",11/23/2022,,N/A,"Environmental Scan and Quality Initiatives to Improve Cancer Screening Rates in New 
York State"
Unknown Sites,I-63018,"Glaser, K",05/23/2018,,N/A,Understanding health behaviors and perceptions of cancer in non-English speaking populations
Lung,P-76718,"Goniewicz, M",11/27/2018,,N/A,"CONNECT (Clinical Outcomes of Nationwide, Naturalistic E-Cig Trial)"
Lung,I-2588022,"Goniewicz, M",06/23/2022,,N/A,"A randomized, parallel-group open-label trial of ENDS users switching from flavors of potentially high-toxicity profile to flavors of potentially low-toxicity profile (CRoFT_3.2)"
Unknown Sites,I-1574221,"Goniewicz, M",08/31/2021,,N/A,"Comparing Nicotine Delivery, Subjective Effects, and Sensory Experiences of Tobacco 
Users Using Oral Nicotine Products and Electronic Cigarettes [ZYN Study]"
Lung,I-70618,"Goniewicz, M",08/30/2018,06/13/2022,N/A,"Changes in respiratory symptoms and inflammation markers among e-cigarette users during spontaneous ""switching"" between flavors (CRoFT_3.1)"
Other Female Genital,I-59317,"Goniewicz, M",08/21/2018,,N/A,Electronic Cigarette Use During Pregnancy
Unknown Sites,P-522019,"Goniewicz, M",11/15/2019,,N/A,International E-cigarette Study - Youth
Other Urinary,N-1353721,"Gopalakrishnan, D",08/30/2021,11/29/2022,III,(A031901) DURATION OF IMMUNE CHECKPOINT THERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA: A RANDOMIZED PHASE 3 NON-INFERIORITY TRIAL (IMAGINE)
Bladder,N-1690021,"Gopalakrishnan, D",03/15/2022,,II/III,EA8192 A Phase II/III trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
"Leukemia, other",P-756220,"Green, S",02/15/2021,,I,A Phase 1b Study of ABBV-744 Alone or in Combination with Ruxolitinib or Navitoclax in Subjects with Myelofibrosis
"Leukemia, other",P-622220,"Green, S",12/17/2020,,I,"A Phase 1/2, Open-label, Dose escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 3654 in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis"
Myeloid and Monocytic Leukemia,I-54017,"Griffiths, E",10/17/2017,09/16/2022,IV,Evaluation of antibody response to high-dose seasonal influenza vaccination in patients with myeloid malignancy receiving chemotherapy
"Other Hematopoietic; Leukemia, other",P-483719,"Griffiths, E",11/07/2019,,N/A,"An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)"
Myeloid and Monocytic Leukemia; Other Hematopoietic,P-543719,"Griffiths, E",09/16/2020,,I/II,"A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)"
Prostate,P-78418,"Griffiths, E",11/25/2019,10/31/2022,I/II,"A randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)"
Myeloid and Monocytic Leukemia,P-810020,"Griffiths, E",04/02/2021,,I,"A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia"
"Leukemia, other",P-1263721,"Griffiths, E",10/25/2021,,II/III,"A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis"
,I-1151721,"Griffiths, E",03/12/2021,,N/A,Evaluation of Immune Responses to COVID-19 Vaccination in Patients with Cancer
Multiple,I-449719,"Griffiths, E",02/10/2020,,N/A,Evaluation of patients with hematopoietic disorders and their family members for known or suspected inherited predisposition.
"Leukemia, other",PH-213112,"Griffiths, E",04/22/2013,,N/A,Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
"Leukemia, other",P-2074121,"Griffiths, E",05/23/2022,,N/A,Study evaluating the prevalence of the KIT D816V mutation in peripheral blood of patients with evidence of systemic mast cell activation (MCA)
Unknown Sites,I-67818,"Grimmer, J",03/21/2019,06/23/2022,N/A,Routine nurse-led follow up in a chronic cancer pain management clinic for patients started on adjuvant neuropathic pain medications: Are patient outcomes improved?
,I-875720,"Gupta, A",03/08/2021,,N/A,(MCC-20320) Blood based biomarkers for minimal residual disease detection in pediatric sarcomas
Soft Tissue,N-979720,"Gupta, A",05/07/2021,12/27/2022,II,"(A091902) A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naïve, and Nivolumab and Carbozantinb in Taxane Pretreated Subjects With Angiosarcoma"
Soft Tissue,N-2224021,"Gupta, A",12/16/2021,,III,"(ARST2031) A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)"
Soft Tissue,IC-1588021,"Gupta, A",08/08/2022,,II,"Evolutionary inspired therapy for newly diagnosed, metastatic, Fusion Positive Rhabdomyosarcoma"
Bones and Joints,IC-1706021,"Gupta, A",03/09/2022,,I/II,"MCC 19487 A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma"
Multiple Sites,I-2144021,"Gupta, A",02/16/2022,,N/A,Roswell Park Pediatric and Adolescent and Young Adult (AYA) Data Registry
Bladder,I-258714,"Guru, K",10/01/2015,,N/A,Assessment of Circulating Tumor Cells in Blood and Irrigation Fluid During Robot-Assisted Radical Cystectomy
Kidney,I-53605,"Guru, K",04/14/2005,,N/A,Kidney Cancer Database and Use of Existing Tissue Resources 1983-Present
Bladder,I-573720,"Guru, K",08/04/2020,,IV,Does Prophylactic Antibiotic Decrease the Rate of Urinary Tract Infection after Robot Assisted Radical Cystectomy
Prostate,I-822320,"Guru, K",11/30/2020,,N/A,Investigating the correlation between the Brain and Pelvic Floor Muscle Activity of Patients Undergoing Robot-Assisted radical Prostatectomy
Bladder,P-48517,"Guru, K",03/30/2018,,II,CA-ALT-803-01-16 QUILT-3.032:  A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 (N-803) in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Prostate,I-198211,"Guru, K",09/13/2011,,N/A,Prostate Cancer Database: Clinical Parameters
Unknown Sites,I-241913,"Guru, K",07/17/2013,,N/A,"Evaluation and Assessment of Cognition, Perception, and Motor Skills during Robot Assisted Surgery"
Unknown Sites,I-244113,"Guru, K",07/01/2014,,N/A,Observational Study to Identify Patterns in Communication and Team Interaction in the Operating Room
Multiple,I-461719,"Guru, K",10/23/2019,,N/A,Understanding How Visual Imagery Can Impact Training in Robot Assisted Surgery
Bladder,I-53017,"Guru, K",03/01/2018,,N/A,Spatial Analysis of Bladder Cancer in Western New York
Prostate,I-77718,"Guru, K",01/09/2019,,N/A,Impact of a National Comprehensive Cancer Network Compliant Multidisciplinary Consortium on Treatment Decisions in Patients with Localized Prostate Cancer
,I-73418,"Hahn, T",07/13/2021,10/07/2022,N/A,INSPIRE: A Multicenter Randomized Controlled Trial integrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantation
Other Hematopoietic,IC-1052320,"Hahn, T",09/09/2021,,N/A,A Prospective Analysis of Biochemical Markers for Hematopoietic Cell Transplant-Associated Thrombotic Microangiopathy in Adults
,I-810620,"Haring, R",01/08/2021,,N/A,A Novel Sugar-Sweetened Beverage Reduction Intervention for Native American Men
"Non-Hodgkin's Lymphoma; Leukemia, other",CIC-01-16,"Hernandez, F",08/24/2001,,N/A,Collection of Blood from Healthy Donors and Patients with Lymphoma and Leukemia to Study the Immunological Activity of Peripheral Blood Mononuclear cells (PBMC) and Human Serum
Non-Hodgkin's Lymphoma,I-42804,"Hernandez, F",02/11/2005,,N/A,Evaluation of Changes in The Structure of CD20 and Downstream Signaling in Patients with Rituximab Resistant/Refractory B-Cell Lymphomas and Leukemia
Non-Hodgkin's Lymphoma,N-2076021,"Hernandez, F",09/09/2022,,II,(A051902) A RANDOMIZED PHASE II STUDY OF CHO(E)P VS CC-486-CHO(E)P VS DUVELISIB-CHO(E)P IN PREVIOUSLY UNTREATED CD30 NEGATIVE PERIPHERAL T-CELL LYMPHOMAS
Lymphoid Leukemia,N-563819,"Hernandez, F",08/12/2020,10/04/2022,II/III,A051701Randomized phase II/III study of venetoclax (ABT 199) plus chemoimmunotherapy for MYC/BCL2 double-hit and double-expressing lymphomas
Other Hematopoietic,N-83919,"Hernandez, F",04/22/2019,07/06/2022,III,(A041702) A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 65 Years of Age)With Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma,N-2076021-S,"Hernandez, F",09/09/2022,,II,A RANDOMIZED PHASE II STUDY OF CHO(E)P VS CC-486-CHO(E)P VS DUVELISIB-CHO(E)P IN PREVIOUSLY UNTREATED CD30 NEGATIVE PERIPHERAL T-CELL LYMPHOMAS
Other Hematopoietic; Hodgkin's Lymphoma,I-503719,"Hernandez, F",05/28/2021,,II,A Phase II Study of Pembrolizumab and Entinostat in Patients with Relapsed and Refractory Lymphomas (17-073)
Non-Hodgkin's Lymphoma; Lymphoid Leukemia,I-69018,"Hernandez, F",03/08/2019,01/06/2022,I,"A Phase I Study of pevonedistat (MLN4924, TAK924) in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and non-Hodgkin lymphoma"
Multiple,P-439919,"Hernandez, F",08/12/2020,,N/A,Long-Term Follow-Up Protocol for Subjects Treated with Gene-Modified T Cells
Non-Hodgkin's Lymphoma,P-1325721,"Hernandez, F",10/14/2022,,II,"(CLOVER-WaM) An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia"
Non-Hodgkin's Lymphoma,P-1053420,"Hernandez, F",02/02/2022,,III,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma"
Non-Hodgkin's Lymphoma,P-809820,"Hernandez, F",11/16/2021,02/21/2023,III,"A Phase 3, multicenter, randomized, double-blind, placebo- controlled trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high- risk patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)"
Non-Hodgkin's Lymphoma,I-1279721,"Hernandez, F",07/02/2021,,N/A,"Prospective, observational, non-interventional feasibility study of Minimal Residual Disease assessment with CAncer Personalized Profiling by deep sequencing in patients with newly diagnosed peripheral T cell lymphoma."
Unknown Sites,I-270115,"Herr, M",04/04/2016,,N/A,A Preliminary Study to Determine the Effect of Donor and Recipient Vaccinations on Clinical and Laboratory Outcomes after Autologous and Allogeneic Hematopoietic Cell Transplant
"Lip, Oral Cavity and Pharynx",I-281415,"Hicks, W",04/05/2016,,N/A,"Clinical and Pathological Prognosticators of Incidence, Progression and Survival in Head and Neck Cancers and Indications and Outcomes of Cancer-Related Plastic/Reconstructive Surgery"
Multiple Sites,I-66418,"Hillengass, J",03/04/2019,,N/A,Characterization of Focal Lesions in Monoclonal Plasma Cell Disorders over the Course of the Disease
Multiple Myeloma,I-47217,"Hillengass, J",06/25/2018,08/26/2022,II,Phase II Study of Targeting CD28 in Multiple Myeloma with Abatacept (CTLA4-Ig) to Overcome Resistance to Chemotherapy
Multiple Myeloma,I-247913,"Hillengass, J",03/09/2016,06/21/2022,I,"A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in  patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy"
Multiple Myeloma,I-797720,"Hillengass, J",12/05/2022,,II,Phase 2 Trial of Belantamab Mafoditin Consolidation Treatment in Patients with Multiple Myeloma and MRD Positivity after Autologous Stem Cell Transplantation
Multiple Myeloma,I-1680221,"Hillengass, J",06/28/2022,,N/A,Improving Host Factors in Patients with Monoclonal Gammopathies
Multiple Myeloma,I-70118,"Hillengass, J",09/05/2019,08/23/2022,N/A,Feasibility of Strength Training and Impact on Pain and Quality of Life in Patients with Multiple Myeloma
Multiple Myeloma,IC-1654021,"Hillengass, J",06/03/2022,,II,"Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs. Carfilzomib, Lenalidomide, and Dexamethasone in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE)"
Multiple Myeloma; Other Hematopoietic,P-432519,"Hillengass, J",12/10/2019,08/12/2022,I,"A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY OF CC-99712, A BCMA ANTIBODYDRUG CONJUGATE, IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA"
Multiple Myeloma,P-821720,"Hillengass, J",10/26/2021,,I/II,"A PHASE 1/2 MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CC-92480 MONOTHERAPY AND IN COMBINATION WITH DEXAMETHASONE IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (CC-92480-MM-00)"
Multiple Myeloma,P-1668021,"Hillengass, J",11/17/2022,,II,A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma
Multiple Myeloma,P-555719,"Hillengass, J",01/22/2021,,I/II,"A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory  Multiple Myeloma (HPN217-3001)"
Multiple Myeloma,P-550219,"Hillengass, J",06/11/2020,02/21/2023,II,"A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma"
Multiple Myeloma,P-1173921,"Hillengass, J",04/28/2022,,III,"A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis"
Multiple Myeloma,P-846420,"Hillengass, J",02/22/2021,06/10/2022,N/A,Health Related Quality of Life in Multiple Myeloma
Unknown Sites,I-37216,"Hiscock, M",01/24/2017,08/15/2022,N/A,Moral Distress in Nurses providing direct patient care on inpatient oncology units and outpatient clinics
Multiple,I-40916,"Ho, C",12/07/2017,09/02/2022,II,A PHASE II TRIAL OF HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION UTILIZING MOBILIZED PERIPHERAL BLOOD STEM CELLS.
Multiple Sites,I-44417,"Ho, C",08/03/2017,02/22/2023,I/II,A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation with Post Transplant Cyclophosphamide as Graft versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation
Multiple Myeloma,P-1059520,"Ho, C",12/06/2022,,I,(FT576-101) A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
Multiple Myeloma,IC-1207721,"Ho, C",03/16/2022,,II,Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomide BMT CTN Protocol #1902
,I-673720,"Hong, C",07/06/2020,12/12/2022,N/A,Women's Health after Breast Cancer II Study: Understanding How Adrenergic Stress Influences Breast Cancer Prognosis
,I-839720,"Hutson, A",01/12/2021,,N/A,Coordinating and Data Management Center for Acquired Resistance to Therapy Network (ARTNet)
,I-806620,"Hyland, A",01/06/2021,01/10/2023,N/A,Educating Smokers about Lung Cancer Screening using Tobacco Quitlines
Lung,I-279415,"Ivanick, N",02/04/2020,,II,Endobronchial Ultrasound Transbronchial Needle guided Interstitial Photodynamic Therapy for Palliation of Locally Advanced Lung Cancer and Advanced Cancers Obstructing the Airway -Phase I/IIa Study
Lung,I-62305,"Ivanick, N",07/26/2005,,N/A,Lung Bronchoscopy Research Samples & Database
Lung,P-1261721,"Ivanick, N",12/24/2021,11/16/2022,N/A,Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the Lung
Lung,P-1431721,"Ivanick, N",12/07/2021,,N/A,"Collection of human-derived, healthy and disease-specific biological samples for the development and control of laboratory assays, procedures and general research"
Multiple,I-70218,"Iyer, R",11/05/2018,,N/A,Roswell Park Neuroendocrine Tumor Biobank
Pancreas,N-74618,"Iyer, R",10/31/2018,,III,"(A021602) RANDOMIZED, DOUBLE-BLINDED PHASE III STUDY OF CABOZANTINIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS AFTER PROGRESSION ON PRIOR THERAPY"
Multiple,N-641920,"Iyer, R",08/12/2020,09/09/2022,II,"EA2187,  A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma"
Small Intestine,IC-2482222,"Iyer, R",04/18/2022,,II,"ETCTN,(NCI 10476) A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers"
Other Endocrine System,N-2390021,"Iyer, R",05/24/2022,,II/III,: (S2012) Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
,P-973720,"Iyer, R",10/05/2021,12/20/2022,II,(HCRN GI19-405) A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC)
Multiple,I-64518,"Iyer, R",06/17/2019,,II,"Phase 2 Single-Arm Study of Nanoliposomal Irinotecan with Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin"
Liver,I-35316,"Iyer, R",09/13/2017,,I/II,A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
Multiple,I-79518,"Iyer, R",06/13/2019,,I,A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients with Metastatic Neuroendocrine Tumors (NETs)
Liver,I-646120,"Iyer, R",02/01/2022,,II,UPCC 04219: Phase 2 Study of Capecitabine-Temozolomide(CapTem) with yttrium-90 Radioembolization in the Treatment of Patients with Unresectable Metastatic Grade 2 Neuroendocrine Tumors
Liver,P-521819,"Iyer, R",09/04/2020,09/02/2022,I/II,"A Phase 1b/2, Open-Label, Study of Tivozanib in Combination with Durvalumab in Subjects with  Advanced Hepatocellular Carcinoma"
,IC-2478021,"Iyer, R",11/07/2022,,II,"A Phase II Randomized Study of Atezolizumab plus Multi-Kinase Inhibitor versus Multi-Kinase Inhibitor Alone in Subjects with Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab"
Other Endocrine System,P-2016021,"Iyer, R",02/10/2022,05/30/2022,N/A,An Expanded Access Program of Surufatinib for Patients with Advanced or Metastatic Neuroendocrine Tumors
Lung,N-1527721,"Jain, P",07/19/2021,05/20/2022,II,"S1900E, A PHASE II STUDY OF SOTORASIB (AMG 510) IN PARTICIPANTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY)"
Lung,P-2128221,"Jain, P",05/10/2022,,N/A,"Deep learning-Enabled Exploration of Predictive signatures in a multicenter retrospective and prospective observational study allowing the analysis of the aggregation of multimodal clinical, biological, genomic and radiomics data associated with the response to treatment and prognosis of patients with stage IV non-small cell lung cancer"
,I-255314,"Kane, J",06/24/2014,,N/A,"Tissue Procurement Protocol for the Developmental Therapeutics Clinic, NCI"
,N-825920,"Kelly, K",02/22/2021,,I/II,"A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma"
Hodgkin's Lymphoma,N-529719,"Kelly, K",12/20/2019,12/01/2022,III,"(S1826) A PHASE III, RANDOMIZED STUDY OF NIVOLUMAB (OPDIVO) PLUS AVD OR BRENTUXIMAB VEDOTIN (ADCETRIS) PLUS AVD IN PATIENTS (AGE >/= 12 YEARS) WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA (NCT03907488)"
Lymphoid Leukemia,I-48717,"Kelly, K",08/29/2017,03/09/2023,N/A,Implementing a Low Glycemic Diet in Children and Adolescents Undergoing Treatment for Acute Lymphoblastic Leukemia
,I-841820,"Kelly, K",04/02/2021,,N/A,(SPARK Cluster RCT) Symptom Screening Linked to Care Pathways for Children with Cancer: a Cluster Randomized Trial
Lymphoid Leukemia,I-43517,"Kelly, K",09/01/2017,09/12/2022,III,DFCI ALL Consortium 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Hodgkin's Lymphoma,P-489819,"Kelly, K",03/03/2020,07/28/2022,II,"An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)"
Lung,P-824220,"Keppel, A",01/28/2021,03/16/2022,N/A,GAPPS: Guidance And Preparation for Patients with Non-Small Cell Lung Cancer: Pilot Study
Unknown Sites,I-270915,"Kisailus, A",12/28/2015,08/01/2022,N/A,"The Impact of Summer Research Experience Programs on Preparing and Encouraging High School, Undergraduate and Medical Students for Advanced Education and Careers in Cancer Research"
Multiple,P-1221720,"Krishnamurthy, A",03/31/2022,,I,"A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors"
Prostate,N-1347921,"Kuettel, M",05/27/2021,,III,"NRG-GU009: PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)
*Prostate RNA Expression/Decipher To Individualize Concurrent Therapy with Radiation"
Prostate,N-2606022,"Kuettel, M",12/05/2022,,III,"NRG-GU010: PARALLEL PHASE III RANDOMIZED TRIALS OF GENOMIC RISK STRATIFIED UNFAVORABLE INTERMEDIATE RISK PROSTATE CANCER: DE-INTENSIFICATION AND INTENSIFICATION CLINICAL 
TRIAL EVALUATION (GUIDANCE)"
Prostate,N-2610122,"Kuettel, M",10/12/2022,,II,"NRG-GU011: A PHASE II DOUBLE-BLINDED, PLACEBO CONTROLLED TRIAL OF PROSTATE OLIGOMETASTATIC 
RADIOTHERAPY WITH OR WITHOUT ANDROGEN 
DEPRIVATION THERAPY IN OLIGOMETASTATIC PROSTATE 
CANCER (NRG PROMETHEAN)"
Prostate,N-509819,"Kuettel, M",12/16/2019,05/11/2022,II,"NRG-GU007,RANDOMIZED PHASE II TRIAL OF NIRAPARIB WITH STANDARD COMBINATION RADIOTHERAPY AND ANDROGEN DEPRIVATION THERAPY (ADT) IN HIGH RISK PROSTATE CANCER (WITH INITIAL PHASE I) (NADIR*)
*Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I)"
Esophagus,I-283516,"Kukar, M",12/30/2016,07/15/2022,II,"Double-arm, Randomized Study of Botulinum Toxin Injection as a Pyloric Drainage Procedure for Minimally Invasive Esophagectomy (Phase II)"
Unknown Sites,I-268815,"Lau, J",06/05/2015,,N/A,Platelets in Extrinsic Glycosylation
Colon,P-2114021,"Lee, K",09/19/2022,,N/A,"Effects of aNaesthesia in COloREctal cancer outcome trial - ENCORE The effects of anaesthetic techniques on time to start of adjuvant chemotherapy,  and early and late outcomes following surgery for colorectal cancer (Stage I - III)"
Other Female Genital,N-1660021,"Lele, S",09/28/2021,,II,"NRG-GY023: A RANDOMIZED PHASE II TRIAL OF TRIPLET THERAPY (A PD-L1 INHIBITOR DURVALUMAB (MEDI4736) IN COMBINATION WITH OLAPARIB AND CEDIRANIB) COMPARED TO OLAPARIB AND CEDIRANIB OR DURVALUMAB (MEDI4736) AND CEDIRANIB OR STANDARD OF CARE CHEMOTHERAPY IN WOMEN WITH PLATINUM-RESISTANT RECURRENT EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL OR FALLOPIAN CANCER WHO HAVE RECEIVED PRIOR BEVACIZUMAB (NCT#04739800)"
Other Female Genital; Ovary,N-55817,"Lele, S",03/08/2018,09/22/2022,III,"(NRG-GY006) A Randomized phase III trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, or stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal cancer"
Cervix Uteri,N-830320,"Lele, S",03/01/2021,,N/A,"NRG-GY022, Assessment of carboplatin clearance predictors: a PK study on NCI-sponsored clinical trials or standard of care treatments using carboplatin (NCT# 03997370)"
Breast,N-1274321,"Levine, E",05/27/2021,,III,"(A011801) The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib"
Lung,N-2020021,"Levine, E",,,III,Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Breast,NCG-245113,"Levine, E",04/08/2014,07/01/2022,III,(A011202) A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 NI) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Multiple Sites,NCG-275215,"Levine, E",06/01/2016,,N/A,(EAY 131 Master Protocol) Molecular Analysis for Therapy Choice (MATCH)
Brain and Nervous System,N-76518,"Levine, E",07/09/2019,,III,(COG #AGCT1532) Phase 3 Accelerated BEP Trial:A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
Breast,N-646320,"Levine, E",06/25/2020,,II,EA1181 (CompassHER2 pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
Breast,N-431719,"Levine, E",07/08/2019,05/20/2022,III,"NRG-BR004,""A Randomized, Double-Blind, Phase III Trial of 
Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line 
HER2-Positive Metastatic Breast Cancer,"" (NCT03199885)"
Breast,N-50117,"Levine, E",07/27/2017,08/10/2022,II,NRG-BR005: A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery
Breast,NCG-275415,"Levine, E",03/03/2016,05/18/2022,III,A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Other Urinary,N-1497721,"Levine, E",07/15/2021,09/12/2022,III,"S1937,A PHASE III RANDOMIZED TRIAL OF ERIBULIN (NSC #707389) WITH OR WITHOUT GEMCITABINE VERSUS STANDARD OF CARE (PHYSICIAN S CHOICE) FOR TREATMENT OF METASTATIC UROTHELIAL CARCINOMA REFRACTORY TO, OR INELIGIBLE FOR, ANTI PD1/PDL1 THERAPY"
Breast,P-924220,"Levine, E",10/05/2022,,III,"GO42784: A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER"
Breast,P-622020,"Levine, E",02/03/2021,07/11/2022,II,PrE0113:A study to assess overall response rate by inducing an inflammatory phenotype in Metastatic BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti-PD-L1 Avelumab and Paclitaxel BRACELET-1 Study
Breast,P-48217,"Levine, E",07/23/2018,,N/A,"MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)"
Multiple,P-81418,"Lipinski, L",03/12/2019,,N/A,3D Prediction of Patient-specific Response using Ex vivo Interrogation of Live Cells from Tumors
Lung,IC-2416121,"Mahoney, M",09/26/2022,,II,"Phase II Randomized, Double Blind, Placebo-Controlled Trial of the Broccoli Seed and Sprout Extract (BSSE), Avmacol ES, to Evaluate Sustained Detoxification of Tobacco Carcinogens in Heavy Smokers"
Lung; Unknown Sites,I-476019,"Malik, N",11/07/2019,09/19/2022,N/A,Initial Development and Validation of a Hemoptysis Evaluation Tool
Other Hematopoietic,I-57217,"McCarthy, P",04/18/2019,,Early Phase I,A Pilot Study generating a biorepository to correlate Bio Markers and outcomes of Cellular Therapy Patients
Multiple,N-429819,"McCarthy, P",09/11/2019,05/16/2022,N/A,(BMTCTN 1702) Clinical Transplant - Related Long-term Outcomes of Alternative Donor Allogenic Transplantation ( CTRL-ALT-D)
,I-78618,"McCarthy, P",12/19/2019,01/11/2022,II,"A Phase II Multicenter, Single Arm, Open-Label Trial to Evaluate the Efficacy and Safety of Denosumab in Treatment of Post-Allogenic Hematopoietic Stem Cell Transplant Bone Loss"
Non-Hodgkin's Lymphoma,P-867120,"McCarthy, P",03/09/2021,,I,A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9 Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies
Multiple Myeloma,P-612020,"McCarthy, P",11/11/2020,09/14/2022,I,"A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CC-98633, BCMA-TARGETED NEX-T CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS, IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA"
Other Hematopoietic,P-707720,"McCarthy, P",05/13/2021,,N/A,EXPANDED ACCESS PROTOCOL (EAP) FOR PATIENTS RECEIVING LISOCABTAGENE MARALEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE (JCAR017-EAP-001)
"Myeloid and Monocytic Leukemia; Leukemia, other",P-2258921,"McCarthy, P",10/17/2022,02/17/2023,I/II,"A PHASE I/II, DOSE-ESCALATION STUDY OF MGTA-117 IN PATIENTS WITH ADULT ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASIA-EXCESS BLASTS (MDS-EB)"
Multiple,IC-1950021,"McCarthy, P",12/20/2022,,II,"ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies"
Non-Hodgkin's Lymphoma; Lymphoid Leukemia,P-80318,"McCarthy, P",02/27/2019,,N/A,"Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release"
"Leukemia, other",NCG-202611,"McCarthy, P",10/19/2011,,N/A,(CIBMTR 10-CBA) A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
Other Hematopoietic,NCG-00403,"McCarthy, P",03/28/2003,,N/A,"Center for International Blood and Marrow Transplant Research Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries"
"Lip, Oral Cavity and Pharynx",N-842020,"McSpadden, R",03/09/2021,,III,NRG HN006:RANDOMIZED PHASE II/III TRIAL OF SENTINEL LYMPH NODE BIOPSY VERSUS ELECTIVE NECK DISSECTION FOR EARLY-STAGE ORAL CAVITY CANCER
Prostate,P-42116,"Mohler, J",08/10/2017,03/15/2022,III,A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
,I-2618422,"Morrison, C",03/17/2022,04/26/2022,N/A,Roswell Rapid Heme Panel (RRHP)
Ovary,EPR-01103,"Moysich, K",05/20/2003,,N/A,Novel Risk Factors and Potential Early Detection Markers for Ovarian Cancer
Colon,N-59217,"Mukherjee, S",04/26/2018,05/17/2022,III,(A021502) Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch
Anus,N-1001720,"Mukherjee, S",02/12/2021,,III,EA2176  A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients
Anus,I-76618,"Mukherjee, S",12/13/2018,03/25/2022,II,(NCI 9673)  Part B: A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal (Amendment)
Stomach; Esophagus,I-533819,"Mukherjee, S",01/08/2021,,II,Phase II study of short course FOLFOX chemotherapy with either Nivolumab or Nivolumab + Radiation in the first line treatment of metastatic or unresectable gastroesophageal cancers (BMS Protocol CA209-76L).
Stomach; Esophagus,I-443819,"Mukherjee, S",12/10/2019,11/17/2022,II,Use of Trifluridine/tipiracil (TAS-102) and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and gastroesophageal junction (GEJ) adenocarcinoma
Multiple,P-457819,"Mukherjee, S",06/04/2020,,I,"A Phase I/IIa, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors"
Stomach; Esophagus,P-781620,"Mukherjee, S",03/03/2022,11/28/2022,II/III,"SGNTUC-022: A randomized, double-blind, placebo-controlled, active comparator Phase 2/3 study of tucatinib in combination with trastuzumab, ramucirumab, and paclitaxel in subjects with previously treated, locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC)"
,N-635920,"Mukherjee, S",01/13/2021,,N/A,A151804: ESTABLISHMENT OF A NATIONAL BIOREPOSITORY TO ADVANCE STUDIES OF IMMUNE-RELATED ADVERSE EVENTS
Esophagus,I-57817,"Mukherjee, S",01/18/2018,,N/A,The Roswell Park Barrett's and Esophageal Adenocarcinoma Registry (RP-BEAR)
Prostate,I-285716,"Nastiuk, K",09/21/2017,,N/A,Alteration of Serum Cytokines During ADT in Treatment-Naive Prostate Cancer Patients
Multiple,I-517819,"Nwogu, C",06/05/2020,08/18/2022,N/A,Technology Enhanced Multidisciplinary Oncology Care
"Melanoma, Skin",N-2898822,"O'Brien, S",09/13/2022,,III,"S2015: Melanoma Margins Trial (MelMart): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1CM V 2CM Wide Excision Margins for Primary Cutaneous Melanoma"
,I-757820,"O'Connor, R",12/04/2020,09/29/2022,N/A,Effects of filter ventilation and ventilation information on product use behaviors in cigarette smokers (COMET 2 3.1)
Unknown Sites,I-471719,"O'Connor, R",10/07/2019,,N/A,Nicotine Vapor Specific Sensory Measurement
Unknown Sites,I-72518,"O'Connor, R",08/29/2019,,N/A,Methods for characterizing flavor impact on user behavior and perceptions
Unknown Sites,I-80518,"O'Connor, R",09/19/2019,,N/A,Consumer Assessment of Tobacco Flavor and Odor
Unknown Sites,I-68718,"O'Connor, R",10/23/2018,07/12/2022,N/A,"Effects of filter ventilation on sensory response, smoking topography, and inhalation (COMET 2 2.1)"
Unknown Sites,I-1389821,"O'Connor, R",05/17/2021,,N/A,Web Based Surveys to Assess Perceptions and Intention to Use Emerging Heated Tobacco and Oral Nicotine Products
,I-567719,"O'Connor, R",07/20/2020,,N/A,New York State Health Behavior and Policy Survey
Breast,I-778720,"O'Connor, T",12/22/2020,,II,"A Phase IIA Trial Assessing the Tolerability of Abemaciclib in Combination with 
Endocrine Therapy in Patients Age 70 and Older with Hormone Receptor Positive 
Metastatic Breast Cancer Who Have Progressed on or After Prior CDK 4/6 Inhibition"
Breast,I-32816,"O'Connor, T",10/06/2017,,N/A,Exercise to Improve Health and Quality-of-life in Breast Cancer Survivors:  A Feasibility Pilot Trial
Breast,I-67518,"O'Connor, T",11/09/2018,06/02/2022,N/A,Exercise and Nutrition Intervention in Older Breast Cancer Survivors
Breast,P-887720,"O'Connor, T",08/23/2021,01/21/2022,N/A,EndoPredict® Extended Endocrine Trial (EXET): A prospective registry to evaluate the impact of the EndoPredict® test on extended endocrine treatment decisions and patient outcomes
Other Female Genital; Ovary,I-45717,"Odunsi, K",04/12/2018,02/04/2022,N/A,TISSUE AND DATA ACQUISITION ACTIVITY FOR THE STUDY OF GYNECOLOGIC DISEASE
Breast; Stomach,I-79218,"Ozturk, C",02/07/2019,,N/A,Comparing Unilateral and Bilateral Deep Inferior Epigastric Perforators (DIEP) Flaps for unilateral breast reconstruction
Other Skin,P-2234022,"Paragh, G",11/29/2022,,II,CEMIPLIMAB SURVIVORSHIP EPIDEMIOLOGY (CASE) STUDY
Lung,I-208611,"Pokharel, S",04/24/2012,,N/A,European Thoracic Oncology Platform (ETOP) Lungscape Master Protocol
Brain and Nervous System,N-3256822,"Prasad, D",11/07/2022,,III,A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases (NRG-BN012)
Lung,N-642120,"Prasad, D",08/05/2020,08/16/2022,III,(S1827)MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
,N-2218522,"Przespolewski, A",11/07/2022,,I/II,NCI 10417; Clinical Evaluation of ASTX727 in combination with Venetoclax all oral therapy vs standard of care Cytarabine and Anthracycline Induction Chemotherapy for younger FLT3WT patients with Acute Myeloid Leukemia
Myeloid and Monocytic Leukemia,I-501719,"Przespolewski, A",05/15/2020,,II,A Phase II Study of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia
Myeloid and Monocytic Leukemia,P-1305721,"Przespolewski, A",02/08/2022,,I/II,A Phase 1/2 Study of ALX148 in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia (AML)
Myeloid and Monocytic Leukemia,P-1367721,"Przespolewski, A",01/28/2022,02/23/2023,I,"A Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of MK-0482 in Participants with Relapsed or Refractory Acute Myeloid Leukemia"
Myeloid and Monocytic Leukemia,I-694020,"Przespolewski, A",03/26/2021,,N/A,Treatment practices and outcomes of adults with therapy-related acute myeloid leukemia (AML) and AML with myelodysplasia related changes
"Brain and Nervous System; Melanoma, Skin",N-913820,"Puzanov, I",02/23/2021,07/20/2022,II,(S2000) A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases
"Melanoma, Skin",N-1021720,"Puzanov, I",02/22/2021,07/20/2022,II,EA6192: A Phase II Study of Biomarker Driven Early Discontinuation of anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
Multiple Sites,N-45117,"Puzanov, I",06/30/2017,03/09/2022,I/II,(S1609) DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
"Melanoma, Skin",N-84019,"Puzanov, I",06/24/2019,05/05/2022,II,(S1801) A PHASE II RANDOMIZED STUDY OF ADJUVANT VERSUS NEOADJUVANT Pembrolizumab (MK-3475) FOR CLINICALLY DETECTABLE STAGE III-IV HIGH RISK MELANOMA
,I-82419,"Puzanov, I",08/22/2022,,II,"A Phase II Study of Type-1 Polarized Dendritic Cell (&#945;DC1) -based Treatment in 
Combination with Tumor-Selective Chemokine Modulation (CKM: Interferon alpha-2b, 
Rintatolimod and Celecoxib) in Melanoma Patients with Primary PD-1/PD-L1 Resistance"
Pancreas; Multiple Sites,P-73618,"Puzanov, I",02/07/2019,08/31/2022,I,"ADCT-301-103: A Phase 1b, Open-Label, Dose-Escalation and DoseExpansion Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine
(ADCT-301) as Monotherapy or in Combination in Patients With
Selected Advanced Solid Tumors"
Multiple Sites,P-2240621,"Puzanov, I",10/25/2022,,I,"A Phase 1 Study of AGEN2373, an Anti-CD137 Monoclonal Antibody, as Monotherapy and in Combination with AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody, in Patients with Advanced Cancer"
Multiple Sites,P-719720,"Puzanov, I",01/22/2021,02/07/2023,I,"D7880C00001 An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination with Durvalumab in Participants with Select Advanced/Metastatic Solid Tumors"
Multiple Sites,P-721020,"Puzanov, I",02/19/2021,12/09/2022,I,CI-8993-101 Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients with Advanced Solid Tumor Malignancies
"Melanoma, Skin",P-1764022,"Puzanov, I",08/17/2022,,III,"An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (advanced) melanoma"
"Melanoma, Skin",P-47916,"Puzanov, I",04/06/2018,08/03/2022,II,"The PISCES Study: A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment"
Multiple,P-553719,"Puzanov, I",06/29/2020,11/30/2022,Early Phase I,"ONCR-177-101 A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination with PD-1 Blockade in Adult Subjects with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors"
Multiple,P-2208021,"Puzanov, I",09/15/2022,,I/II,"A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Cancers"
Multiple,P-1075721,"Puzanov, I",03/25/2022,,I/II,"A PHASE 1A OPEN-LABEL, DOSE-ESCALATION, AND A PHASE 2 STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF ST-067 ADMINISTERED SUBCUTANEOUSLY AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS"
Multiple Sites,IC-1269722,"Puzanov, I",09/29/2022,,N/A,"URCC-21038: Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT):
A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting"
"Lung; Melanoma, Skin",P-1646021,"Puzanov, I",07/06/2022,,N/A,PROPHETIC   Predicting responsiveness in oncology patients based on host response evaluation during anti cancer treatments
Unknown Sites,I-60717,"Quinn, T",08/28/2018,09/14/2022,IV,General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial:  Pragmatic Randomized Trial of Propofol vs Volatile Inhalational Anesthesia
Unknown Sites,I-75418,"Quisenberry, A",10/01/2018,,N/A,"Flavored Tobacco Product Regulation: Behavioral Economic Demand, Visual Attention, and Flavored Tobacco Product Availability"
Unknown Sites,I-475819,"Quisenberry, A",12/31/2019,,N/A,"Pharmacokinetics, subjective effects, and abuse liability of nicotine salt-based vaping products with tobacco or unflavored e-liquids [SALTVAPE Study]"
Unknown Sites,I-477719,"Quisenberry, A",09/12/2019,,N/A,Determining the appeal and abuse liability of heated tobacco products: qualitative and behavioral economic evaluation of the role of flavor
,I-806120,"Quisenberry, A",02/17/2021,,N/A,Substitutability of Cigarettes for Salt- and Free-Base Ends Devices in Young Adult Ends Users in a Menthol Flavor Ban
,I-650320,"Quisenberry, A",08/26/2020,,N/A,Evaluation of tobacco product litter policy within an Experimental Tobacco Marketplace
Unknown Sites,I-694620,"Quisenberry, A",09/16/2020,01/03/2023,N/A,A sugar-sweetened beverage (SSB) marketplace for diverse adults
Lung,I-511919,"Reid, M",03/19/2021,,Early Phase I,A Phase 0 Study of CIMAvax-EGF vaccine in Patients Who Are At High Risk for Lung Cancer and Lung Cancer Survivors at Risk for Recurrence
Lung,I-96706,"Reid, M",02/07/2007,01/05/2022,N/A,The Stacey Scott  Lung Cancer Registry
Unknown Sites,I-2132221,"Riebandt, G",12/16/2021,08/18/2022,N/A,Identifying Best Practices in Oncology Biosimilar Implementation
Unknown Sites,I-1998021,"Rodriguez, E",11/13/2021,,N/A,Implementation of Evidence-Based Strategies to Optimize HPV Vaccination in Rural Primary Care Settings
,I-2540122,"Rodriguez, E",04/13/2022,,N/A,The Perceived Barriers and Opportunities for HPV Vaccine Delivery Among Pediatric Oncologists in Cancer Care Settings
Unknown Sites,NCG-246313,"Rokitka, D",11/14/2013,07/21/2022,N/A,(COG ALTE11C2) Health Effects After Anthracycline and Radiation Therapy (HEART):  Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy
Lymphoid Leukemia,N-58317,"Rokitka, D",01/31/2018,,N/A,(ALTE1631) A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Cancer
Multiple Sites,N-925420,"Rokitka, D",01/14/2021,,III,(ALTE2031) StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors
Other Respiratory and Intrathoracic Organs,NCG-287516,"Rokitka, D",09/21/2016,01/25/2021,II,(COG ALTE1621) Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
Unknown Sites,I-69418,"Rokitka, D",01/18/2019,09/02/2022,N/A,Aromatherapy: An Integrative Option for Symptom Management in Cancer Care
Other Male Genital,N-80818,"Rokitka, D",01/30/2019,09/01/2022,N/A,(ALTE16C1) Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
Kidney,POG-9442,"Rokitka, D",05/22/1995,01/30/2021,N/A,(CHOB 291) National Wilms Tumor # 5:  Late Effects Study
Unknown Sites,I-186310,"Rokitka, D",05/20/2011,07/21/2022,N/A,Examining Quality of Life Among Long-Term Survivors of Childhood Cancer
Other Hematopoietic,N-50517,"Ross, M",03/14/2018,10/10/2022,II,(BMT CTN Protocol 1507) Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease
Other Hematopoietic,I-905720,"Ross, M",06/28/2021,11/09/2022,II,"Randomized, placebo-controlled, phase II trial examining ustekinumab for prevention of graft vs. host disease after allogeneic hematopoietic cell transplantation"
Myeloid and Monocytic Leukemia; Other Hematopoietic,P-635720,"Ross, M",08/29/2022,,III,"A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia (AML)"
,P-869720,"Ross, M",07/27/2021,,N/A,Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commercial Release (bb2121-EAP-001)
Multiple,P-463719,"Ross, M",02/24/2021,02/25/2022,I,"A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF EFMARODOCOKIN ALFA IN COMBINATION WITH STANDARD OF CARE IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION"
"Myeloid and Monocytic Leukemia; Leukemia, other",P-788620,"Ross, M",02/25/2022,05/24/2022,I,Phase 1 Study of Escalating Single and Multiple Doses of Mana 312 (Multi Tumor-Associated Antigen T cells) Administered to Adult Subjects with Acute Myeloid Leukemia or Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplant
Unknown Sites,I-1968021,"Schneller, L",11/03/2021,,N/A,Focus Groups to Evaluate Consumer Reactions to Tobacco 21 and Contemporaneous Effects
Multiple Sites,I-659920,"Segal, B",09/04/2020,,I/II,Phase 1/2A Study of Rintatolimod and IFN alpha Regimen in Cancer Patients with Mild or Moderate COVID-19 Infection
Lung,I-65718,"Sheffer, C",09/04/2018,,N/A,Enhancing Relapse Prevention with rTMS: Dose-Response Parameters for Smoking Cessation
Lung,I-82819,"Sheffer, C",05/03/2019,,N/A,Promising methods to decrease delay discounting and reduce relapse to smoking
,I-455719,"Sheffer, C",12/18/2019,,N/A,Cancer Research Education Curriculum Development Project
,I-2678022,"Sheffer, C",05/19/2022,,N/A,Pilot Study Examining Product Demand Characteristics for Tobacco and Cannabis Co-Use
,I-2684022,"Sheffer, C",10/12/2022,,N/A,Pilot Study of Episodic Future Thinking among Cigarette Smokers
Unknown Sites,I-64918,"Sheffer, C",06/21/2018,,N/A,Evaluation of Roswell Park Cessation Services
Multiple,I-290616,"Sherrow, C",10/12/2016,09/28/2022,N/A,Conventional vs iPad-based Education for Gastrointestinal Cancer Patients Undergoing Chemotherapy: A Non-Interventional Study
"Lip, Oral Cavity and Pharynx; Esophagus",N-505719,"Singh, A",11/01/2019,,II/III,"EA3161: A Phase III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA"
Multiple,N-66918,"Singh, A",06/10/2019,,II,EA3163:Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC)
Multiple,N-2266021,"Singh, A",01/18/2022,,II/III,"NRG-HN009: RANDOMIZED PHASE II/III TRIAL OF RADIATION WITH 
CISPLATIN AT 100 MG/M2 EVERY THREE WEEKS VERSUS RADIATION WITH WEEKLY CISPLATIN AT 40 MG/M2 FOR PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)"
"Lip, Oral Cavity and Pharynx",N-61217,"Singh, A",04/04/2019,09/01/2022,II/III,(NRG-HN004) Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
Multiple,N-798320,"Singh, A",01/28/2021,,III,"PROTOCOL RTOG 1216: RANDOMIZED PHASE II/III TRIAL OF ADJUVANT RADIATION THERAPY WITH CISPLATIN, DOCETAXEL-CETUXIMAB, OR CISPLATIN-ATEZOLIZUMAB IN PATHOLOGIC HIGH-RISK SQUAMOUS CELL CANCER OF THE HEAD AND NECK (NCT 01810913)"
Multiple,I-56617,"Singh, A",06/18/2018,02/28/2023,N/A,A Pilot Study of Photoacoustic Imaging (PAI)
"Lip, Oral Cavity and Pharynx",I-48917,"Singh, A",04/02/2018,02/28/2023,Early Phase I,A Pilot Study of Photoacoustic Imaging (PAI) in H&N Cancer Patients
,I-79318,"Singh, A",05/06/2021,04/25/2022,N/A,Survivor Warming to AlteR Mood (S-WARM)
Esophagus,I-630420,"Singh, A",04/01/2021,,II,Propranolol with Standard Chemoradiation for Esophageal Adenocarcinoma - A Combined Single Arm and Randomized Cohort Phase II Study
Lung,I-1307721,"Singh, A",12/16/2021,,N/A,A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer
"Lip, Oral Cavity and Pharynx; Larynx",I-2272021,"Singh, A",09/26/2022,,N/A,Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification (INSIGHT)
Lung,I-50717,"Singh, A",12/18/2017,01/25/2023,Early Phase I,Three Pilot Studies of Stereotactic Body Radiation Therapy (SBRT) and Surgery in Non-Small Cell Lung Cancer
Multiple Sites,I-81318,"Singh, A",11/18/2019,,II,A Phase 2 Randomized Study with a non-Randomized Cohort: Assessing Single-fraction SBRT versus STandard PalliativE Radiation In Patients with Metastatic Disease (ASTEROID)
Lung,I-81919,"Singh, A",11/06/2019,,I,A Feasibility and Toxicity Analysis of Single Fraction Stereotactic Body Radiation Therapy for Post-Operative Non-Small Cell Lung Cancer
Unknown Sites,I-45417,"Singh, A",05/23/2017,02/14/2023,N/A,Understanding the Prevalence of Malnutrition Risk Among Cancer Patients Undergoing Radiation Treatment at RPCI
Multiple Sites,I-60017,"Skitzki, J",07/01/2019,,I,"A Single-center Phase I Dose Escalation/Response Trial to Evaluate the Safety, Tolerability, and Anti-tumor Efficacy of Intra-arterial CBL0137 for Patients with Advanced Extremity Melanoma or Sarcoma"
Unknown Sites,I-1239721,"Smith, D",03/30/2021,,N/A,Prevalence and Perceptions of Cannabis Use among Cancer Patients
Multiple Sites,I-2028021,"Storer, A",02/09/2022,06/14/2022,N/A,"Temperature Measurement, comparison study of 4 different methods"
Prostate,I-44117,"Sumlin, A",08/29/2017,,N/A,Race and geographic differences in diagnosis with metastatic Prostate cancer and early detection
Prostate,I-76918,"Sumlin, A",01/04/2019,,N/A,The Impact of Financial Distress on Prostate Cancer Treatment: A Feasibility Study
Myeloid and Monocytic Leukemia,N-79018,"Thompson, J",12/19/2018,10/20/2022,II,(S1712) A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
Myeloid and Monocytic Leukemia,I-537719,"Thompson, J",12/03/2020,,II,Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
"Leukemia, other",IC-2944822,"Thompson, J",11/10/2022,,II,Asciminib as Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase
Other Hematopoietic,NCG-288816,"Thompson, J",01/06/2017,,N/A,The National Myelodysplastic Syndromes (MDS) Study
Non-Hodgkin's Lymphoma,IC-1197721,"Torka, P",02/02/2022,05/23/2022,II,A Phase 2 Study of Acalabrutinib and PI3K delta inhibitor Umbralisib in Combination with Ublituximab (AU2) in Patients with Previously Untreated Mantle Cell Lymphoma
Non-Hodgkin's Lymphoma; Myeloid and Monocytic Leukemia,I-573919,"Torka, P",09/23/2020,04/29/2022,I,An Investigator-Sponsored Phase Ib Trial of Venetoclax and SINE: Selective Inhibition of Nuclear Export in Patients with High Risk Hematologic Malignancies (VICC HEM1755)
Unknown Sites,I-217912,"Travers, M",08/07/2012,08/17/2022,N/A,Evaluating Tobacco Product Displays in the Retail Environment
Unknown Sites,I-106907,"Travers, M",07/20/2007,06/17/2022,N/A,Evaluation of Smoker Reactions to Novel Tobacco Products
Brain and Nervous System,COG-ANBL00B1,"Twist, C",04/17/2001,,N/A,(CHOB 665) Neuroblastoma Biology Studies
Kidney,NCG-77006,"Twist, C",05/30/2006,,N/A,"(COG AREN03B2/CHOB 2061) Renal Tumors Classification, Biology and Banking Study"
Non-Hodgkin's Lymphoma,N-2216221,"Twist, C",12/16/2021,,III,(ANHL1931) A Randomized Phase 3 trial of Nivolumab (NSC#748726 IND#125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Myeloid and Monocytic Leukemia,N-2246021,"Twist, C",12/16/2021,,II,(AAML18P1) Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Brain and Nervous System,N-2366021,"Twist, C",03/15/2022,,III,"(ACCL2031) A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors"
Multiple Sites,N-2428222,"Twist, C",03/21/2022,,I/II,"(PEPN2111) A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma"
Brain and Nervous System,N-2960822,"Twist, C",11/29/2022,,I/II,(ACNS1821) A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Brain and Nervous System,N-2960822-A,"Twist, C",11/29/2022,,I/II,[SAFETY PHASE] (ACNS1821) A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Brain and Nervous System,N-479919,"Twist, C",12/10/2019,,II,"(COG ANBL1821) A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma"
Multiple Sites,N-52617,"Twist, C",11/09/2017,,III,AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Multiple Sites,N-55017,"Twist, C",01/09/2018,,N/A,(APEC1621) NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
,N-55017-B,"Twist, C",03/10/2022,,N/A,APEC1621B NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) - PHASE 2 SUBPROTOCOL OF JNJ-42756493 (ERDAFITINIB) IN PATIENTS WITH TUMORS HARBORING FGFR1/2/3/4 ALTERATIONS
,N-55017-D,"Twist, C",03/04/2020,,II,(APEC1621D) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF LY3023414 IN PATIENTS WITH SOLID TUMORS
,N-55017-F,"Twist, C",03/10/2022,,II,(APEC1621F) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF ENSARTINIB IN PATIENTS WITH TUMORS HARBORING ALK OR ROS1 GENOMIC ALTERATIONS
,N-55017-G,"Twist, C",03/02/2022,03/02/2022,II,(APEC1621G) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF VEMURAFENIB IN PATIENTS WITH TUMORS HARBORING BRAF V600 MUTATIONS
,N-55017-H,"Twist, C",03/02/2022,03/02/2022,II,(APEC1621H) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF OLAPARIB IN PATIENTS WITH TUMORS HARBORING DEFECTS IN DNA DAMAGE REPAIR GENES
,N-55017-I,"Twist, C",07/25/2022,07/25/2022,N/A,"(APEC1621I), NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes"
Multiple,N-55017-SC,"Twist, C",01/09/2018,,II,(APEC1621SC) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL
Lymphoid Leukemia,N-56517,"Twist, C",12/20/2018,,II,"(AALL1621) A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)"
Lymphoid Leukemia,N-57617,"Twist, C",04/04/2018,,III,AALL1631 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
Brain and Nervous System,N-58017,"Twist, C",01/31/2018,,II,ACNS1422 A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Brain and Nervous System,N-608820,"Twist, C",05/13/2020,,II,(ACNS1723) A Phase 2 Study of Dabrafenib (NCS#763760) with Trametinib (NCS# 763093) after Local Irradiation in Newly-Diagnosed BRAFv600-Mutant High-Grade Glioma (HGG) (IND#145355)
Lymphoid Leukemia,N-609220,"Twist, C",04/29/2020,,III,"AALL1732, A Phase 3 Randomized Trial of Inotuzumab Ozogamicin(IND#:133494, NSC#:772518)for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-InductionTherapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy"
Brain and Nervous System,N-71718,"Twist, C",07/18/2018,,III,(ANBL1531) A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
Liver,N-74918,"Twist, C",10/11/2018,,II/III,(COG AHEP1531) Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
"Leukemia, other",N-784720,"Twist, C",10/13/2020,,III,"(AAML1831) A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations"
Kidney,N-871820,"Twist, C",12/16/2020,,II,Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Soft Tissue,N-924720,"Twist, C",02/25/2021,,II,"(ARST1921) A Safety, Pharmacokinetic and Efficacy Study of a gamma-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375),in Children and Adolescents with  progressive, Surgically Unresectable Desmoid Tumors"
Brain and Nervous System,NCG-272315,"Twist, C",06/19/2015,,III,(COG ANBL1232) Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
Myeloid and Monocytic Leukemia,NCG-289616,"Twist, C",02/13/2017,04/15/2022,III,(COG AAML1531) Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Soft Tissue,NCG-290716,"Twist, C",02/08/2018,,III,"(COG ARST1431) A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)"
"Leukemia, other",P-715820,"Twist, C",02/21/2022,,I/II,"AAML1921, A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921"
Brain and Nervous System,IC-1398121,"Twist, C",06/08/2022,,I,"(PBTC-060) A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma"
"Lymphoid Leukemia; Leukemia, other",I-431919,"Twist, C",07/08/2020,,I,Phase I trial of ribociclib in combination with everolimus and dexamethasone in children and young adults with relapsed acute lymphoblastic leukemia
Lymphoid Leukemia,PH-286916,"Twist, C",09/08/2017,11/29/2022,II,INCB 18424-269 (COG AALL1521) A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway Mutant Acute Lymphoblastic Leukemia
Lymphoid Leukemia,P-507919,"Twist, C",12/17/2020,,II,(AALL1721) A Phase II trial of tisagenlecleucel in first-line high risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy
Other Hematopoietic,P-2530022,"Twist, C",10/25/2022,,III,"TAK-755A Phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS-13, also known as BAX 930/SHP655) in the prophylactic and on-demand treatment of subjects with severe congenital thrombotic thrombocytopenic purpura (cTTP; Upshaw-Schulman Syndrome, or hereditary thrombotic thrombocytopenic purpura)"
Unknown Sites,NCG-279615,"Twist, C",03/09/2016,,N/A,"(COG APEC14B1) The Project:  Everychild Protocol:  A Registry, Eligibility Screening, Biology and Outcome Study"
Colon,N-3076822,"Vadehra, D",11/22/2022,,II,"S2107 Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer"
Unknown Sites,I-629020,"Walter, M",09/16/2020,07/15/2022,N/A,A Survey to Determine Cancer Patients  Perceptions of the Difficulties Encountered When Filling Opioid Prescriptions
Lymphoid Leukemia,N-57017,"Wang, E",08/20/2018,,III,(A041501) A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
"Lymphoid Leukemia; Leukemia, other",N-2012021,"Wang, E",12/22/2021,10/20/2022,I/II,A Phase I/II Study of AKR1C3-Activated Prodrug Obi-3424 (Obi-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
Lymphoid Leukemia; Myeloid and Monocytic Leukemia,I-497719,"Wang, E",03/18/2021,,I,A Phase 1 Study of ABL001 in combination with dasatinib and prednisone in patients with BCR-ABL positive (BCR-ABL+) B-cell acute lymphoblastic leukemia (B-ALL) and chronic myeloid leukemia (CML)
Myeloid and Monocytic Leukemia; Other Hematopoietic,I-435819,"Wang, E",07/23/2020,,I,Phase 1/1b Trial of Talazoparib and Gemtuzumab ozogamicin in Adult Patients with Relapsed and/or Refractory Acute Myeloid Leukemia
Myeloid and Monocytic Leukemia,P-481719,"Wang, E",04/08/2021,02/21/2023,I,"A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Acute Myeloid Leukemia"
Myeloid and Monocytic Leukemia,P-53517,"Wang, E",11/01/2018,,III,"(ARO-013) Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects = 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia"
Myeloid and Monocytic Leukemia,P-52217,"Wang, E",09/11/2018,,III,(ARO-021) Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
Myeloid and Monocytic Leukemia,P-771920,"Wang, E",06/17/2022,,I,"Phase I, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with Relapsed/Refractory Acute Myeloid Leukemia"
Myeloid and Monocytic Leukemia,P-567819,"Wang, E",08/18/2020,,I,"A PHASE I MULTI-DOSE STUDY OF HUMAN PLACENTAL HEMATOPOIETIC STEM CELL 
DERIVED NATURAL KILLER CELLS (CYNK-001) WITH OR WITHOUT RECOMBINANT HUMAN  INTERLEUKIN-2 (RHIL-2) IN ADULTS WITH PRIMARY OR SECONDARY ACUTE MYELOID LEUKEMIA (AML) IN MORPHOLOGIC COMPLETE REMISSION WITH MINIMAL RESIDUAL DISEASE (MRD) OR RELAPSED/REFRACTORY AML"
"Myeloid and Monocytic Leukemia; Leukemia, other",P-507719,"Wang, E",02/21/2020,01/07/2022,I,A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination with Azacitidine in Patients with Hematological Malignancies
"Leukemia, other",P-550019,"Wang, E",02/03/2021,09/20/2022,III,"A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome"
Myeloid and Monocytic Leukemia,P-1187721,"Wang, E",05/25/2022,10/25/2022,II,A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Myeloid Malignancies
Myeloid and Monocytic Leukemia,P-487719,"Wang, E",02/04/2020,,I/II,A phase Ib/2 study of IMGN632 as monotherapy or combination with venetoclax and/or azacitidine for patients with CD123+ AML
Myeloid and Monocytic Leukemia,P-57117,"Wang, E",07/11/2018,09/19/2022,I,"A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients with CD123-positive Acute Myeloid Leukemia and Other CD123- positive Hematologic Malignancies"
Myeloid and Monocytic Leukemia,P-1333721,"Wang, E",12/09/2021,,III,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3K; Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis"
Myeloid and Monocytic Leukemia,P-84119,"Wang, E",09/04/2019,,I/II,A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
"Myeloid and Monocytic Leukemia; Leukemia, other",P-810220,"Wang, E",12/14/2021,,I,A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations
"Myeloid and Monocytic Leukemia; Leukemia, other",P-46617,"Wang, E",01/10/2018,06/30/2022,I/II,Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML) or Myelofibrosis (MF)
Myeloid and Monocytic Leukemia,P-1397721,"Wang, E",04/11/2022,,II,Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who are Ineligible for Standard Induction Therapy
"Leukemia, other",P-1397921,"Wang, E",05/12/2022,,I,"A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients with Advanced Hematologic Malignancies, Including Lymphoma, Leukemia, and Multiple Myeloma"
Breast,I-571719,"Witkiewicz, A",07/03/2020,,N/A,The Roswell Park Ciclib Study: A Prospective Study of Biomarkers and Clinical Features of Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.
"Lip, Oral Cavity and Pharynx",I-67918,"Wooten, K",01/17/2019,,II,"A Randomized, Multi-Center Phase 2 Trial with a Phase 1 Safety Run-in: Porfimer Sodium Mediated Interstitial Photodynamic Therapy and Standard of Care (SoC) Therapy versus SoC Therapy alone for the Treatment of Patients with Locally Advanced or Recurrent Head and Neck Cancer."
"Melanoma, Skin",I-287416,"Wooten, K",09/15/2016,08/02/2022,N/A,Treatment Outcomes in Cutaneous Melanoma of the Head and Neck
Lung,N-780320,"Yau, E",10/26/2020,,III,Protocol (A081801) Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC:ALCHEMIST Chemo-IO (ACCIO)
Lung,N-19-04259,"Yau, E",05/08/2019,,II/III,(LUNGMAP) A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LungMAP Screening Study)
Lung,P-487819,"Yau, E",04/06/2020,,I/II,A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Bladder,I-661820,"Yeary, K",08/25/2020,,I,POW-R Health: Power to Redefine your Health (Internal Title: A Pragmatic Dietary Intervention to Improve Bladder Cancer Survivorship)
,I-684220,"Yeary, K",08/25/2020,,N/A,Weight loss interventions for black adults of faith
Multiple Sites,I-66018,"Yendamuri, S",02/07/2019,,N/A,Endoscopy Sample Collection Protocol
Lung,I-72818,"Yendamuri, S",01/22/2019,,II,Preoperative Respiratory Muscle Training to Prevent Postoperative Pulmonary Complications in Patients Undergoing Resection for Lung Cancer
Lung,IC-2064121,"Yendamuri, S",03/31/2022,,N/A,METFORMIN FOR CHEMOPREVENTION OF LUNG CANCER IN HIGH-RISK OBESE INDIVIDUALS
,I-62118,"Yendamuri, S",09/17/2021,,I,"Light Dosimetry for Intraoperative Photodynamic Therapy (IO-PDT) with Porfimer 
Sodium (Photofrin®) in Patients with Malignant Mesothelioma, Non-Small Cell Lung 
Cancer (NSCLC), or Other Malignancies with Pleural Disease - Phase I Study"
Lung,I-767720,"Yendamuri, S",11/05/2021,,I,"Utilizing Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients 
with Non-Small Cell Lung Cancer (NSCLC) with Pleural Disease or Malignant Pleural 
Mesothelioma (MPM) - Phase I Study"
Multiple Sites,I-215512,"Zsiros, E",02/14/2014,,N/A,"Analysis of Tumor Antigens, Immunity, and Genetic Changes in Gynecological Cancer Patients"
Multiple,P-762420,"Zsiros, E",03/17/2022,08/19/2022,I,"20190131 A Phase 1, Multicenter, Open-label,Dose-Exploration and Dose-Expansion Study Evaluating the Safety,Tolerability,Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors"
Cervix Uteri,P-38016,"Zsiros, E",07/07/2017,,II,"A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma"
Ovary,P-1882021,"Zsiros, E",08/30/2022,,III,"A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96 / ENGOT-ov65)"
Multiple,P-1391721,"Zsiros, E",05/20/2022,,I/II,"NC762-01 A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects with Advanced or Metastatic Solid Tumors"
Multiple,P-2058021,"Zsiros, E",07/29/2022,,I,A Phase 1 Safety and Tolerability Study of DeTIL-0255 in Adults with Advanced Malignancies
Multiple,P-1263921,"Zsiros, E",02/18/2022,12/07/2022,I,"A Phase 1, multicenter, Open-Label Study of SQZ-AAC-HPV as Monotherapy and in Combination with Immune Checkpoint Inhibitors in HLA-A*02+ Patients with HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors"
Corpus Uteri; Ovary,I-37616,"Zsiros, E",12/12/2016,,N/A,Life On The Go 1: Evaluating the Effect of Baseline Physical Activity of Patients with Endometrial and Ovarian Cancer using State of the Art Activity Tracking Device
Unknown Sites,I-56117,"Zsiros, E",06/13/2018,12/14/2022,N/A,The GYN Molecular Information Registry
